Dulcolax

By X. Ningal. Grace University. 2019.

Cox DJ dulcolax 5 mg overnight delivery, Merkel RL generic 5 mg dulcolax overnight delivery, Penberthy JK, Kovatchev B, Hankin CS. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention- deficit/hyperactivity disorder: a pilot study. Journal of the American Academy of Child & Adolescent Psychiatry. A controlled trial of methylphenidate in black adolescents. Pelham WE, Vodde-Hamilton M, Murphy DA, Greenstein J, Vallano G. The effects of methylphenidate on ADHD adolescents in recreational, peer group, and classroom settings. Effects of methylphenidate in adolescents with attention deficit disorder. Journal of the American Academy of Child Psychiatry. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: I. Journal of the American Academy of Child & Adolescent Psychiatry. Attention deficit hyperactivity disorder 135 of 200 Final Update 4 Report Drug Effectiveness Review Project 174. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: II. Journal of the American Academy of Child & Adolescent Psychiatry. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD. Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder. Journal of the American Academy of Child & Adolescent Psychiatry. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD. Methylphenidate speeds evaluation processes of attention deficit disorder adolescents during a continuous performance test. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD. Methylphenidate reduces abnormalities of stimulus classification in adolescents with attention deficit disorder. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo- controlled evaluation of Ritalin side effects. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention- deficit/hyperactivity disorder. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults.

The Ki-67 stain was extremely high but buy 5mg dulcolax fast delivery, unlike BL discount 5 mg dulcolax with mastercard, the cells were CD10 negative and BCL2 positive (not illustrated). Nevertheless, these investigators stated that “… so-called genetic double-hit lymphomas … represent a true oncological challenge and are clearly under-treated by R-CHOP. BCLU with MYC and BCL2 double-hit and MYC and BCL2 Categorization of DHL is controversial. Note the extensive nuclear MYC (B) and cytoplasmic DH, putting all the cases in the BCLU category even if they BCL2 (C) expression fulfilling the criteria for a DE B-cell lymphoma. The morphologically resemble a DLBCL, dividing up the DHL cases lymphoma had a GC-type phenotype (CD10 , BCL6 , IRF4/MUM1 ) with some in each of these 2 categories based on their morphologic and 95% Ki-67-positive cells (not illustrated). Suggested evaluation of large B-cell lymphomas of DLBCL, NOS, and BCLU type Obtain clinical history* Routine histopathology Immunophenotypic studies to assess CD20 expression, cell of origin (CD10, BCL6 and IRF4/MUM1 if using Hans’ algorithm), Ki-67, MYC, BCL2, CD5 and cyclin D1 to accomplish the following: Identify B-cell lineage in absence of T-cell phenotype and required for use of anti-CD20 therapeutic antibodies Cell of origin has prognostic implications in many studies and may impact therapeutic decisions Identify MYC and BCL2 DE cases Identify cases more likely to be DHL/THL (see text and table 4) Identify blastoid and pleomorphic mantle cell lymphomas Identify CD5 DLBCL, a recognized immunophenotypic variant Aid in distinction from Burkitt lymphoma, exclude plasmablastic lymphoma, assist in distinction of other types of large B-cell lymphomas In situ hybridization for Epstein-Barr virus at least in cases that have some polymorphism and patient is 50 years old (rule out EBV DLBCL of the elderly) In the absence of classical cytogenetic studies, cytogenetic FISH studies to identify MYC, BCL2 and BCL6 rearrangements at least in a subset of cases more likely to have a positive yield† such as: All DLBCL with a GC phenotype plus cases of BCLU and/or a combination of the following with any positive finding being followed up with FISH studies (the more parameters selected the more cases tested and the fewer cases missed, none are 100% sensitive) MYC 40% (some recommend 20%) Ki-67 80% (a poor criterion used in isolation) BCL2 strongly positive (will miss most BCL6 DHL, may require use of 1 BCL2 antibody) MYC 40% and BCL2 50% (“DE” cases, see comments re MYC and BCL2 above) Histopathology suggests BCLU If MYC rearrangement is identified, demonstration of translocation partner has been shown to be of importance in limited studies (IGH/ / versus non-immunoglobulin partner) but would be considered more optional at the current time. Specifically, a workup to determine if very aggressive therapies are appropriate is not required if a patient’s performancestatusorothercircumstanceswouldprecludesuchatherapeuticapproach. The criteria, which at least in some studies would be the least predictive, are morphologic features and Ki-67 proportions and for thelesscommonBCL6DHL,BCL2expression. Practice patterns vary widely, even at academic institutions, with “dramatically different and usually rapidly fatal” clinical course many choosing either the second or third options, but with some unlike BL, with a median survival of only 0. Given the uncertainty as to whether morphologic differences matter when it comes to the outcome and It is very difficult to define exactly what cases belong in this potential therapy for DHL, the current interest in identifying DHL intermediate category. A general guideline is to include cases that and the great overlap between the DHL and BCLU cases from many look like BL but in which the phenotype, genotype, and/or perspectives, one could argue that now it is best to put all DHL cases karyotype are too “atypical” or cases with perfect ancillary studies in the BCLU category rather than dividing them up based on a but cytologic features considered beyond what is acceptable for subjective, probably not very reproducible, morphologic distinction. In a group of 48 cases we reviewed, the most frequent differences from a BL BCLU, which some use to describe most, if not all, of their DHL included more pleomorphism and fewer typical intermediate-sized cases, was introduced in the 2008 WHO classification, not as a new cells and either no starry sky or more often only a partial starry sky entity, but as a somewhat vaguely defined and heterogeneous appearance, a lack of amphophilic cytoplasm, and the presence of category for cases that have features intermediate between DLBCL coagulative necrosis (SHS, unpublished data). Therefore, most cases will have a GC The BCLU category does not simply reflect the inadequacies of phenotype and, if misdiagnosed as DLBCL, NOS, one might think modern-day hematopathologists, but acknowledges a gray zone also the patient had a more indolent large B-cell lymphoma when, in documented by gene expression profiling (GEP), which has shown fact, according to many but not all studies, they have a very the existence of a group of lymphomas intermediate between mBL aggressive one. Consistent with the premise that BCLU is not used and DLBCL, clearly not of BL type. Cases of mBL that varies widely in the literature from 33% to 91% (or “most”), with had a histomorphological diagnosis of DLBCL or high-grade B-cell 78% reported in one study to be DHL. Immunophenotypic studies have several potential roles to play in this arena, but also some serious potential pitfalls and unsettled issues. First, IHC and, to a lesser extent, flow cytometric studies have been proposed as rapid and cost-effective screening tools to cut down on the number of FISH studies being used to find DHL/THL. In fact, many have looked for DHL/THL only in BCLU and/or when large B-cell lymphomas have a very high proliferation fraction based on Ki-67 staining, but both strategies will miss a significant minority of DHL/THL. Some DHL/THL cases morphologically resemble other DLBCL cases and many have 90% Ki-67 cells, with some much lower. With a Ki-67 cutoff of 90%, the sensitivity for finding DHL/THL among aggressive B-cell lympho- mas was only 0. It has been reported that finding 70% MYC cells had a sensitivity of 100% and specificity of 93% for a MYC break. Major take-home messages, a personal perspective ● Large B-cell lymphomas that have MYC and either BCL2 and/or less frequently BCL6 rearrangements (DHL or THL) should be recognized using cytogenetic studies because of their very aggressive course in most studies and the need for alternative therapies. These findings suggest that, at the current time, all de novo DHL/THL should be included in the B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL category. Furthermore, their recognition is complicated by issues related to the reproducibility of these immunohistochemical stains due to technical and interpretive factors and a lack of uniform reported cutoffs for positivity. Others have also found that MYC IHC cannot 5-year survivals of only 30%–36% reported. Unlike different laboratories and, in my experience, staining within even the GC predominance in cytogenetically defined DHL, most studies BL can vary based on cell viability and probably fixation-related find that 2/3 of DE DLBCL cases are of the non-GC type. Problems with reproducibility in the use of the 40% cutoff have also been reported53 and Horn et al did write in 2013 that: The potential importance of DE large B-cell lymphomas has been “paying tribute to the fact that only recent and as yet incomplete emphasized, with one report that the prognostic differences between experience has been gained for immunohistochemical stainings with GC and ABC/non-GC DLBCL relate to the latter having more DE the anti-MYC antibody … at the moment we strongly advise the use cases and that, once the DE cases are excluded, there are very of a combined MYC-FISH and IHC model. In an effort to control costs and save time, a low statistical power. Others still recommend 70%, but with most requiring at least 50%. A recent review of Health Organization; 2008:265-266. Double-hit B-cell lympho- for DE lymphomas because “it is not known if its presence mas. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical because DE cases are relatively common, it “may not be feasible to review of cytogenetics in the light of today’s knowledge. Fluorescence significant issues related to the reproducibility in MYC staining and in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue interpretation are discussed in the second paragraph of this section, sections in the diagnostic work-up of non-Burkitt high grade B-cell but also must be considered. I must admit that I find it somewhat non-Hodgkin’s lymphoma: a single centre’s experience. MYC status in concert with BCL2 could make a major difference in a patient’s treatment plan and such and BCL6 expression predicts outcome in diffuse large B-cell lym- decisions are not uncommon in my daily practice. B-cell lymphoma, unclassifiable, Perhaps analogous to the cytogenetic story, some find that MYC with features intermediate between diffuse large B-cell lymphoma and expression by itself ( 40%) is an adverse prognostic indicator that burkitt lymphoma: study of 39 cases.

Quality assessments of randomized controlled trials of beta blockers for arrhythmia Author Eligibility Outcome Care Patient Intention-to- Maintenance of Year criteria assessors provider unaware of treat (ITT) comparable Country Exclusion criteria for recruitment specified blinded blinded treatment analysis groups Head-to- head trials Katritsis Terminal illness quality dulcolax 5mg, age > 80 years cheap 5mg dulcolax visa, left ventricular Yes Yes NR NR No NR 2003 ejection fraction <30, concomitant treatment with class I or III antiarrhythmic drugs, amiodarone use within 3 months before randomization, previous treatment with bisoprolol or carvedilol, and contraindications to beta blockade, such as conduction disturbances, asthma, or severe chronic obstructive pulmonary artery disease Placebo- controlled trials Metoprolol vs placebo Kuhlkamp • Use of Class 1 or 3 antiarrhythmic drug, beta- Yes NR Yes Yes No Yes 2000 blockers or calcium channel blockers; chronic treatment with amiodarone within 6 months. Quality assessments of randomized controlled trials of beta blockers for arrhythmia Reporting of attrition, Differential loss to Control Author crossovers, follow-up or Score group Year adherence, and overall high loss to (good/ fair/ standard of Length of Country contamination follow-up poor) Funding care follow-up Head-to- head trials Katritsis Yes No Fair NR Yes 12 months 2003 No No No No Placebo- controlled trials Metoprolol vs placebo Kuhlkamp Attrition=6. Quality assessments of randomized controlled trials of beta blockers for arrhythmia Author Year Allocation Groups similar Similarity to target Number Country Random assignment concealed at baseline population recruited Metoprolol vs placebo Khand NR NR Yes Mean age=68. Quality assessments of randomized controlled trials of beta blockers for arrhythmia Author Eligibility Outcome Care Patient Intention-to- Maintenance of Year criteria assessors provider unaware of treat (ITT) comparable Country Exclusion criteria for recruitment specified blinded blinded treatment analysis groups Metoprolol vs placebo Khand Heart rate at rest < 60 beats/min, systolic blood Yes Yes Yes Yes Yes NR 2003 pressure < 90 mm Hg, sick sinus syndrome or UK complete heart block, current treatment with a beta- blocker or HR-lowering calcium channel antagonist or > 200 mg amiodarone, recent major cardiovascular event or procedures, asthma or reversible obstructive airways disease, serum creatinine > 250 µmol/l or significant hepatic disease, uncorrected significant valvular heart disease, or any life-threatening noncardiac disease Beta blockers Page 343 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 15. Quality assessments of randomized controlled trials of beta blockers for arrhythmia Reporting of attrition, Differential loss to Control Author crossovers, follow-up or Score group Year adherence, and overall high loss to (good/ fair/ standard of Length of Country contamination follow-up poor) Funding care follow-up Metoprolol vs placebo Khand Yes No Fair Roche Yes Phase I=4 2003 No No Pharmaceuticals months; UK No Phase II=6 No months Beta blockers Page 344 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Year Allowed other Country Interventions (drug, medications/ Study Design Eligibility criteria Exclusion criteria regimen, duration) interventions Fair quality Atenolol Forssman History of migraine (Ad Hoc Committee) NR Atenolol (ate) 100 mg daily Common analgesics and 1982 Placebo (pla) x 90 days; then ergotamine Sweden crossover Fair quality RCT Crossover Beta blockers Page 345 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Fair quality Atenolol Forssman Patient forms: 1) number; 2) intensity Mean age=40 NR NR/NR/24 enrolled 1982 (3-point scale); 3) duration of attacks; 80% female Sweden 4) incapacity for work; 5) medication Race NR Fair quality Integrated headache: score RCT Crossover considering combined effect of intensity and duration Follow-up visits were made after 14, 56, 154, and 254 days Beta blockers Page 346 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Fair quality Atenolol Forssman Dizziness of orthostatic ate=1 1982 type(# pts): ate=6; pla=1 pla=0 Sweden Diffuse tiredness: ate=2; pla=0 Fair quality Mood alterations: ate=1; RCT Crossover pla=0 Beta blockers Page 348 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Bisoprolol van de Ven Patient diary assessed at 4-wk Mean age: bis Family history of migraine(# NR/NR/226 randomized 1997 intervals 5 mg=38. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Bisoprolol van de Ven Adverse event incidence(# Adverse event 1997 patients/%): bis 5 withdrawals(# The Netherlands mg=26/35%; bis 10 patients/%): bis 5 mg=33/43%; pla=25/33% mg=4/74(5. Placebo controlled trials of beta blockers for migraine Author Year Allowed other Country Interventions (drug, medications/ Study Design Eligibility criteria Exclusion criteria regimen, duration) interventions Metoprolol Andersson Outpatients of both sexes, with an age over Other types of vascular headaches, Metoprolol durules (met-d) Acute migraine 1983 16 and below 65 years diagnosed to have chronic daily headache not separable 200 mg daily medication allowed (e. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Metoprolol Andersson Patient diary card: 1) frequency; 2) Mean age: Classical migraine(#pts/%): NR/75 eligible/71 1983 Intensity (1=annoying, but patient not pla=37. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Metoprolol Andersson Incidence(# pts/%): met- Withdrawals(# 1983 d=16(53. Placebo controlled trials of beta blockers for migraine Author Year Allowed other Country Interventions (drug, medications/ Study Design Eligibility criteria Exclusion criteria regimen, duration) interventions Kangasniemi Outpatients aged 16-65 years, diagnosed Daily use of analgesics and/or total Metoprolol durules (met-d) Former acute migraine 1987 as having classic migraine (NIH Ad Hoc consumption exceeding 40 200 mg daily medication allowed (not Scandinavia Committee); 2-8 migraine attacks per tablets/month; daily use of ergotamine Placebo (pla) x 8 weeks, specified) month, of which at least 50% had to be and/or total consumption exceeding 16 then crossover Fair quality accompanied by focal aura symptoms mg/month; treatment with anti- RCT depressive or neuroleptic drugs within the past 2 months; use of narcotic analgestics, chronic treatment with calcium antagonists, clonidine, other beta-blockers or NSAIDSs; change in oral contraceptive therapy 3 months before or during the study; contraindications for beta-blockers; insufficienty treated hypertension; transient ischaemic attacks; epilepsy; hypothyroidism and other severe psychiatric or somatic disease; and pregnancy Beta blockers Page 357 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Kangasniemi Diary card measuring following n=74 Family history: 54(73%) NR/NR/77 randomized 1987 variables: Mean Attacks per month(mean): 4. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Kangasniemi 3 withdrawn(1 due to Outcomes per 4 weeks (mean score/% change) Recorded at each 1987 narcotic abuse and 2 due to Attack frequency: met=1. Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Kangasniemi Adverse effects NR Classic migraine 1987 incidence(% patients): only Scandinavia met=36%; pla=18% Fair quality Most frequent adverse RCT effects(# complaints for weeks 1-4/5-8) Gastrointestinal: met=7/9; pla=1/2 Fatigue: met=6/7; pla=3/1 Cardiovascular: met=1/2; pla=0/3 Sleep disturbances: met=3/1; pla=0/0 Others: met=10/6; pla=7/8 Beta blockers Page 360 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Year Allowed other Country Interventions (drug, medications/ Study Design Eligibility criteria Exclusion criteria regimen, duration) interventions Pindolol Ekbom Aged 19-56, with classic or common Bronchial asthma, severe infectious Group 1: Pindolol (pin1) 7. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Pindolol Ekbom Patient record: 1) frequency, 2) Mean Classic migraine=4(13. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Pindolol Ekbom NR Withdrawals: pin=4; 1971 pla=0 Sweden Withdrawals due to: Fair quality Orthostatic RCT hypotension=2 Increased headache=1 Dizziness/cystopyel itis=1 Sjaastad Untoward effects noted: pin=3/28(10. Placebo controlled trials of beta blockers for migraine Author Year Allowed other Country Interventions (drug, medications/ Study Design Eligibility criteria Exclusion criteria regimen, duration) interventions Propranolol Borgesen Diagnosis of migraine (Ad Hoc Committee Cardiac disease; asthma or diabetes Propranolol (pro) 120 mg Symptomatic treatments 1974 on Classification of Headache, 1962); mellitus; physical or neurological daily allowed (e. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Propranolol Borgesen Patient forms: 1) severity on 3-point Mean Classical migraine (# pts/%): NR/NR/45 entered 1974 scale (severe=forcing patient to stay age=37. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Propranolol Borgesen Data NR; pro=pla for pro=0 1974 #/severity of complaints of pla=2 Denmark fatigue drowsiness and diarrhea Fair quality RCT Crossover Dahlof NR NR Looked at 1987 longlasting Sweden prophylactic effect following Fair quality discontinuance RCT Crossover Beta blockers Page 368 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 16. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment? Placebo controlled trials of beta blockers for migraine Author Withdrawals due Year to adverse events Country (%, adverse Study Design Adverse effects reported n/enrolled n) Comments Diamond Frequency of most Phases I & II 1982 common adverse events(# combined: United States patients/%) pla=3/245(1. Placebo controlled trials of beta blockers for migraine Author Year Age Other population Number screened/ Country Method of outcome assessment Gender characteristics eligible/ Study Design and timing of assessment Ethnicity (diagnosis, etc) enrolled Diener Headache diary Mean age: pro n=78; pla n=55 235/214/214 1996 pro=40; Mean migraine history(years): Germany pla=39 pro=21; pla=19 % female: Migraine with aura(#/% Fair quality pro=76. Placebo controlled trials of beta blockers for migraine Author Number Year withdrawn/ Method of Country lost to fu/ adverse effects Study Design analyzed Outcomes assessment?